Project information | Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] | Guidance

Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor

Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

Status	Discontinued
Technology type	Medicine
Decision	Selected
Process	TA
ID number	517
Referral date	01 November 2011
Topic area	Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Project Team

Communications manager:	TBC
Executive Lead:	TBC
Project manager:	TBC
Technical Lead:	TBC

Email enquiries

If you have any queries please email scheduling@nice.org.uk

Timeline

Key events during the development of the guidance:

Date	Update
31 October 2022	Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022	Discontinued. Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 March 2012	The Institute has now been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for lapatinib in combination with paclitaxel, which was based on the results of the EGF104535 study. Further information is available here. Therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Date

Update

31 October 2022

Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

31 October 2022

Discontinued. Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

21 March 2012

The Institute has now been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for lapatinib in combination with paclitaxel, which was based on the results of the EGF104535 study.

Further information is available here.

Therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual